Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 9

1.

Preclinical evaluation of the immunogenicity of C-type HIV-1-based DNA and NYVAC vaccines in the Balb/C mouse model.

Wild J, Bieler K, Köstler J, Frachette MJ, Jeffs S, Vieira S, Esteban M, Liljeström P, Pantaleo G, Wolf H, Wagner R.

Viral Immunol. 2009 Oct;22(5):309-19. doi: 10.1089/vim.2009.0038.

PMID:
19811088
2.

Influence of antigen exposure on the loss of long-term memory to childhood vaccines in HIV-infected patients.

Puissant-Lubrano B, Combadière B, Duffy D, Wincker N, Frachette MJ, Ait-Mohand H, Verrier B, Katlama C, Autran B.

Vaccine. 2009 Jun 2;27(27):3576-83. doi: 10.1016/j.vaccine.2009.03.050. Epub 2009 Apr 8.

PMID:
19464537
3.

Comparison of human and rhesus macaque T-cell responses elicited by boosting with NYVAC encoding human immunodeficiency virus type 1 clade C immunogens.

Mooij P, Balla-Jhagjhoorsingh SS, Beenhakker N, van Haaften P, Baak I, Nieuwenhuis IG, Heidari S, Wolf H, Frachette MJ, Bieler K, Sheppard N, Harari A, Bart PA, Liljeström P, Wagner R, Pantaleo G, Heeney JL.

J Virol. 2009 Jun;83(11):5881-9. doi: 10.1128/JVI.02345-08. Epub 2009 Mar 25.

4.

EV02: a Phase I trial to compare the safety and immunogenicity of HIV DNA-C prime-NYVAC-C boost to NYVAC-C alone.

McCormack S, Stöhr W, Barber T, Bart PA, Harari A, Moog C, Ciuffreda D, Cellerai C, Cowen M, Gamboni R, Burnet S, Legg K, Brodnicki E, Wolf H, Wagner R, Heeney J, Frachette MJ, Tartaglia J, Babiker A, Pantaleo G, Weber J.

Vaccine. 2008 Jun 13;26(25):3162-74. doi: 10.1016/j.vaccine.2008.02.072. Epub 2008 May 6.

PMID:
18502003
5.

EV01: a phase I trial in healthy HIV negative volunteers to evaluate a clade C HIV vaccine, NYVAC-C undertaken by the EuroVacc Consortium.

Bart PA, Goodall R, Barber T, Harari A, Guimaraes-Walker A, Khonkarly M, Sheppard NC, Bangala Y, Frachette MJ, Wagner R, Liljeström P, Kraehenbuhl JP, Girard M, Goudsmit J, Esteban M, Heeney J, Sattentau Q, McCormack S, Babiker A, Pantaleo G, Weber J; EuroVacc Consortium.

Vaccine. 2008 Jun 13;26(25):3153-61. doi: 10.1016/j.vaccine.2008.03.083. Epub 2008 May 27.

PMID:
18502002
6.

Immunogenicity of a thermally inactivated rotavirus vaccine in mice.

Jiang B, Wang Y, Saluzzo JF, Bargeron K, Frachette MJ, Glass RI.

Hum Vaccin. 2008 Mar-Apr;4(2):143-7. Epub 2007 Nov 4.

PMID:
18382129
7.

An HIV-1 clade C DNA prime, NYVAC boost vaccine regimen induces reliable, polyfunctional, and long-lasting T cell responses.

Harari A, Bart PA, Stöhr W, Tapia G, Garcia M, Medjitna-Rais E, Burnet S, Cellerai C, Erlwein O, Barber T, Moog C, Liljestrom P, Wagner R, Wolf H, Kraehenbuhl JP, Esteban M, Heeney J, Frachette MJ, Tartaglia J, McCormack S, Babiker A, Weber J, Pantaleo G.

J Exp Med. 2008 Jan 21;205(1):63-77. doi: 10.1084/jem.20071331. Epub 2008 Jan 14.

8.

Generation and immunogenicity of novel HIV/AIDS vaccine candidates targeting HIV-1 Env/Gag-Pol-Nef antigens of clade C.

Gómez CE, Nájera JL, Jiménez V, Bieler K, Wild J, Kostic L, Heidari S, Chen M, Frachette MJ, Pantaleo G, Wolf H, Liljeström P, Wagner R, Esteban M.

Vaccine. 2007 Mar 1;25(11):1969-92. Epub 2006 Dec 6.

PMID:
17224219
9.

Head-to-head comparison on the immunogenicity of two HIV/AIDS vaccine candidates based on the attenuated poxvirus strains MVA and NYVAC co-expressing in a single locus the HIV-1BX08 gp120 and HIV-1(IIIB) Gag-Pol-Nef proteins of clade B.

Gómez CE, Nájera JL, Jiménez EP, Jiménez V, Wagner R, Graf M, Frachette MJ, Liljeström P, Pantaleo G, Esteban M.

Vaccine. 2007 Apr 12;25(15):2863-85. Epub 2006 Oct 16.

PMID:
17113200

Supplemental Content

Loading ...
Support Center